0001867096-24-000017.txt : 20240131 0001867096-24-000017.hdr.sgml : 20240131 20240131170513 ACCESSION NUMBER: 0001867096-24-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shannon John Patrick Jr CENTRAL INDEX KEY: 0001553595 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 24583843 MAIL ADDRESS: STREET 1: DURATA THERAPEUTICS, INC. STREET 2: 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR CITY: MORRISTOWN STATE: NJ ZIP: 07960 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871082097 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 4 1 wk-form4_1706738697.xml FORM 4 X0508 4 2024-01-31 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001553595 Shannon John Patrick Jr C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 0 1 0 0 See Remarks 0 Common Stock 2024-01-31 4 A 0 750000 0 A 2158575 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years. President and Chief Operating Officer /s/ Beth Hecht, as Attorney-in-Fact 2024-01-31